CLAIMS

1. Use of ~~a vector, which comprises~~an adeno-associated virus serotype 2 (AAV2) vector particle which comprises an AAV2 genome or a derivative thereof and a polynucleotide sequence encoding REP1 or a variant thereof having at least 90% homology to SEQ ID NO:3 in the manufacture of a medicament for the treatment or prevention of choroideremia.

~~2. The use of a vector according to claim 1, wherein said derivative is a chimeric, shuffled or capsid modified derivative.~~

~~3. The use of a vector according to claim 1 or 2, wherein said AAV genome is from a naturally derived serotype or isolate or clade of AAV.~~

~~4. The use of a vector according to claim 3, wherein said serotype is AAV serotype 2 (AAV2).~~

2~~5~~. The use of an AAV2 vector according to claim 1~~4~~, which comprises SEQ ID NO: 1 or a derivative thereof wherein said derivative is missing one or more from the group of one inverted terminal repeat (ITR) sequence, the replication (rep) gene sequence and capsid (cap) gene sequence.

3~~6~~. The use of an AAV2 vector particle according to ~~any one of the preceding~~ claim 1 or 2~~s~~, wherein said ~~polynucleotide sequence encodes a polypeptide having at least 70% homology to~~REP1 has the sequence of SEQ ID NO: 3 ~~over its entire sequence~~.

4~~7~~. The use of an AAV2 vector particle according to claim 1 or 2~~6~~, wherein said polynucleotide sequence has at least 9~~7~~0% homology to SEQ ID NO: 2 over its entire sequence.

5~~8~~. The use of an AAV2 vector particle according to any one of the preceding claims, which comprises a promoter sequence operably linked to said polynucleotide sequence encoding REP1 or a variant thereof.

6~~9~~. The use of an AAV2 vector particle according to claim 5~~8~~, wherein said promoter is constitutively active.

7~~10~~. The use of an AAV2 vector particle according to claim 5~~8~~, wherein expression from said promoter is retinal-cell specific.

8~~11~~. The use of an AAV2 vector particle according to any one of ~~the preceding~~ claims 5 to 7, which comprises one or more additional regulatory sequences.

9~~12~~. The use of an AAV2 vector particle according to claim 8~~11~~, which comprises a sequence having at least 70% homology to SEQ ID NO: 5 over its entire sequence.

~~13. The use of a vector according to any preceding claim in the form of a vector particle.~~

~~14. The use of a vector according to claim 13 wherein the vector particle is serotype AAV2.~~

105. The use of an AAV vector particle according to any preceding claim wherein the vector is to be administered to said patient by direct retinal, subretinal or intravitreal injection.

116. The use of a vector particle according to claim 105, wherein said vector is to be administered directly into the subretinal space.